Absci (NASDAQ:ABSI) Stock Price Target Cut by Guggenheim

Absci (NASDAQ:ABSI – Get Free Report) had its price objective reduced by equities researchers at Guggenheim from $15.00 to $14.00 in a research note issued to investors on Monday, MarketBeat reports. The brokerage currently has a “buy” rating on the stock. Guggenheim‘s price objective would indicate a potential upside of 84.70% from the company’s previous close.

Several other research analysts also recently commented on ABSI. Jefferies Financial Group initiated coverage on shares of Absci in a research note on Thursday, October 29th. They issued a “buy” rating and a $14.00 price target on the stock. HC Wainwright reissued a “buy” rating on shares of Absci in a research report on Tuesday, October 20th. BTIG Research reissued a “buy” rating and issued a $16.00 price objective on shares of Absci in a research report on Thursday, November 12th. Wall Street Zen upgraded shares of Absci from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Needham & Company LLC raised their target price on shares of Absci from $11.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 12th. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Absci presently has a consensus rating of “Moderate Buy” and an average price target of $14.90.

Check Out Our Latest Analysis on Absci

Absci Stock Up 1.5%

Shares of Absci stock opened at $7.58 on Monday. The stock’s fifty day moving average is $9.60 and its two-hundred day moving average is $6.85. Absci has a 52 week low of $2.24 and a 52 week high of $12.54. The company has a market capitalization of $1.31 billion, a PE ratio of -9.59 and a beta of 2.22.

Absci (NASDAQ:ABSI – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). The business had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.66 million. Absci had a negative return on equity of 61.60% and a negative net margin of 8,451.31%. As a group, research analysts anticipate that Absci will post -0.76 earnings per share for the current year.

Institutional Trading of Absci

A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Absci in the 2nd quarter worth $141,112,000. Marshall Wace LLP increased its position in Absci by 287.3% during the 3rd quarter. Marshall Wace LLP now owns 1,945,901 shares of the company’s stock valued at $20,957,000 after buying an additional 1,443,494 shares in the last quarter. Integral Health Asset Management LLC increased its position in Absci by 62.5% during the 3rd quarter. Integral Health Asset Management LLC now owns 1,300,000 shares of the company’s stock valued at $14,001,000 after buying an additional 500,000 shares in the last quarter. Parkman Healthcare Partners LLC acquired a new position in Absci during the 2nd quarter valued at about $10,366,000. Finally, Bank of America Corp DE purchased a new stake in Absci in the second quarter valued at about $6,560,000. 52.05% of the stock is currently owned by institutional investors.

About Absci

(Get Free Report)

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.

See Also

Analyst Recommendations for Absci (NASDAQ:ABSI)

Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.